Diagnosing non-hepatocellular carcinoma malignancies on CT/MRI and contrast enhanced ultrasound: the Liver Imaging Reporting and Data System approach

Abstract

The Liver Imaging Reporting and Data System (LI-RADS) provides a stepwise algorithmic approach that is proven to be highly accurate in diagnosing hepatocellular carcinoma (HCC) in patients at risk. An essential and early step in the algorithm is the diagnosis of malignancies other than HCC, such as cholangiocarcinoma and combined tumors, by application of LR-M features and criteria. The LR-M category captures most non-HCC malignancies and some atypical HCCs. The exclusion of non-HCC malignancies is important for maintaining the high specificity of the LR-5, definite HCC category. This review provides an overview of the approach to diagnosing non-HCC malignancies using LI-RADS CT/MRI and contrast enhanced ultrasound algorithms.

Keywords

Magnetic resonance imaging / computer tomography / contrast-enhanced ultrasound

References

[1] El-Serag HB,Landgren O,Henderson L.Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans..Hepatology2009;49:116-23 PMCID:PMC2719902

[2] Yamamoto S,Hai S,Yamamoto T.Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma..Cancer Sci2004;95:592-5

[3] Chernyak V,Kamaya A,Elsayes KM.Liver Imaging Reporting and Data System (LI-RADS) Version 2018: imaging of hepatocellular carcinoma in at-risk patients..Radiology2018;289:816-30 PMCID:PMC6677371

[4] Fraum TJ,Rohe E,Salter A.Differentiation of hepatocellular carcinoma from other hepatic malignancies in patients at risk: diagnostic performance of the liver imaging reporting and data system version 2014..Radiology2018;286:158-72

[5] Tang A,Corwin MT,Dietrich CF.Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review..Radiology2018;286:29-48 PMCID:PMC6677284

[6] Kang Y,Kim SH,Choi BI.Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images..Radiology2012;264:751-60

[7] Peporte AR,Nikolaou K,Zech CJ.Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPA-enhanced MRI..Eur J Radiol2013;82:e101-6

[8] Hwang J,Park MJ,Kim SH.Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI..J Magn Reson Imaging2012;36:881-9

[9] Chong YS,Lee MW,Lee WJ.Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI..Clin Radiol2012;67:766-73

[10] Park HJ,Park MJ.Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma..Abdom Imaging2013;38:793-801

[11] Rimola J,Reig M,de Lope CR.Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma..Hepatology2009;50:791-8

[12] Kim SJ,Han JK,Lee JY.Peripheral mass-forming cholangiocarcinoma in cirrhotic liver..AJR Am J Roentgenol2007;189:1428-34

[13] Nakanuma Y,Zen Y.WHO Classification of tumors. Digestive System Tumors.2019;5th ed.Lyon (France)International Agency for Research on Cancer

[14] Fraum TJ,Ludwig DR,Naeem M.Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors..Eur Radiol2020;30:996-1007

[15] Fowler KJ,Hope TA,Wilson SR.LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma..Abdom Radiol (NY)2018;43:149-57

[16] Horvat N,Long N,Zheng J.Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014..Abdom Radiol (NY)2018;43:169-78 PMCID:PMC6598685

[17] Ludwig DR,Cannella R,Tsai R.Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018..Abdom Radiol (NY)2019;44:2116-32 PMCID:PMC6538452

[18] Shao S,Kuang S,Shan Q.Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection..Bosn J Basic Med Sci2020;Epub ahead of print. doi: 10.17305/bjbms.2019.4576

[19] Lee HS,An C.How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?.Eur Radiol2019;29:2408-16

[20] van der Pol CB,Sirlin CB,Salameh JP.Accuracy of the liver imaging reporting and data system in computed tomography and magnetic resonance image analysis of hepatocellular carcinoma or overall malignancy-a systematic review..Gastroenterology2019;156:976-86

[21] Park YS,Kim BH,Choi JW.Using Gd-EOB-DTPA-enhanced 3-T MRI for the differentiation of infiltrative hepatocellular carcinoma and focal confluent fibrosis in liver cirrhosis..Magn Reson Imaging2013;31:1137-42

[22] Lim S,Park HJ,Choi D.Infiltrative hepatocellular carcinoma on gadoxetic acid-enhanced and diffusion-weighted MRI at 3.0T..J Magn Reson Imaging2014;39:1238-45

[23] Choi SY,Min JH,Jeong WK.Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging..Eur Radiol2018;28:2549-60

[24] Seo N,Rhee H.Hepatic sarcomatoid carcinoma: magnetic resonance imaging evaluation by using the liver imaging reporting and data system..Eur Radiol2019;29:3761-71

[25] Choi SH,Park SH,Yu E.LI-RADS Classification and prognosis of primary liver cancers at gadoxetic acid-enhanced MRI..Radiology2019;290:388-97

[26] Vilana R,Bianchi L,Rimola J.Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound..Hepatology2010;51:2020-2029

[27] Wildner D,Greis C,Neurath MF.CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients - early or late washout matters: a subanalysis of the DEGUM multicenter trial..Ultraschall Med2015;36:132-9

[28] Bhayana D,Jang HJ,Wilson SR.Hypervascular liver masses on contrast-enhanced ultrasound: the importance of washout..AJR Am J Roentgenol2010;194:977-83

[29] Han J,Han F,Yan C.The degree of contrast washout on contrast-enhanced ultrasound in distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma..Ultrasound Med Biol2015;41:3088-95

[30] Li R,Ma KS,Tang CL.Detailed analysis of temporal features on contrast enhanced ultrasound may help differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma in cirrhosis..PLoS One2014;9:e98612 PMCID:PMC4038593

[31] Jang HJ,Burns PN.Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation..Radiology2007;244:898-906

[32] Jang HJ,Burns PN.CEUS: an essential component in a multimodality approach to small nodules in patients at high-risk for hepatocellular carcinoma..Eur J Radiol2015;84:1623-35

[33] Wilson SR,Jang HJ.Enhancement patterns of focal liver masses: discordance between contrast-enhanced sonography and contrast-enhanced CT and MRI..AJR Am J Roentgenol2007;189:W7-12

[34] Wilson SR,Piscaglia F,Jang HJ.CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI..Abdom Radiol (NY)2018;43:127-42

[35] Lyshchik A,Dietrich CF,Kim TK.Contrast-enhanced ultrasound of the liver: technical and lexicon recommendations from the ACR CEUS LI-RADS working group..Abdom Radiol (NY)2018;43:861-79 PMCID:PMC5886815

[36] Kim TK,Wilson SR,Piscaglia F.Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 - a review of important differences compared to the CT/MRI system..Clin Mol Hepatol2017;23:280-9 PMCID:PMC5760002

[37] Yang HK,Jang HJ,Khalili K.Contrast-enhanced ultrasound approach to the diagnosis of focal liver lesions: the importance of washout..Ultrasonography2019;38:289-301 PMCID:PMC6769186

[38] Terzi E,Pompili M,Cabibbo G.Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules..J Hepatol2018;68:485-92

[39] Li F,Liu Y,Zheng W.Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017..Eur Radiol2020;30:461-70

[40] Chen LD,Liang JY,Shen SL.Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: A predictive model using contrast-enhanced ultrasound..World J Gastroenterol2018;24:3786-98 PMCID:PMC6127655

[41] Chen LD,Lin Y,Shen SL.Comparison between M-score and LR-M in the reporting system of contrast-enhanced ultrasound LI-RADS..Eur Radiol2019;29:4249-57

[42] Brunt E,Clavien PA,Goodman Z,Gouw A.cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation..Hepatology2018;68:113-126 PMCID:PMC6340292

[43] Sciarra A,Sempoux C.Updates in the diagnosis of combined hepatocellular-cholangiocarcinoma..Hum Pathol2020;96:48-55

[44] Jung DH,Song GW,Moon DB.Longterm prognosis of combined hepatocellular carcinoma-cholangiocarcinoma following liver transplantation and resection..Liver Transpl2017;23:330-41

[45] Potretzke TA,Doyle MB,Heiken JP.Imaging features of biphenotypic primary liver carcinoma (Hepatocholangiocarcinoma) and the potential to mimic hepatocellular carcinoma: LI-RADS analysis of CT and MRI features in 61 Cases..AJR Am J Roentgenol2016;207:25-31

[46] Wells ML,Chandan VS,Fletcher JG.Biphenotypic hepatic tumors: imaging findings and review of literature..Abdom Imaging2015;40:2293-305

[47] Li F,Han F,Luo RZ.Combined hepatocellular cholangiocarcinoma (Biphenotypic) tumors: potential role of contrast-enhanced ultrasound in diagnosis..AJR Am J Roentgenol2017;209:767-74

[48] Zheng W,Zou XB,Han F.Evaluation of Contrast-enhanced US LI-RADS version 2017: application on 2020 liver nodules in patients with hepatitis B infection..Radiology2020;294:299-307

[49] Abdel Razek AAK,Saleh GA,Shabana W.Interobserver agreement of magnetic resonance imaging of liver imaging reporting and data system version 2018..J Comput Assist Tomogr2020;44:118-23